LENZ Therapeutics (NASDAQ:LENZ) Research Coverage Started at SVB Leerink

SVB Leerink assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $32.00 price objective on the stock.

LENZ has been the subject of several other reports. William Blair started coverage on shares of LENZ Therapeutics in a research note on Monday. They issued an outperform rating for the company. Citigroup assumed coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a buy rating and a $34.00 target price for the company. Finally, Piper Sandler assumed coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They issued an overweight rating and a $28.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of Buy and a consensus price target of $31.33.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $17.70 on Monday. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $29.82. The company has a market capitalization of $147.30 million, a PE ratio of -1.13 and a beta of 0.20.

Insider Activity

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were bought at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.